Negative control for PF CBP1. Exhibits negligible activity at CBP and BRD4. Active Analog also available.
Chekler et al (2015) Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities. Chem.Biol. 22 1588 PMID:26670081
















